Poolbeg Pharma PLC POLB 001 Data Presented at ASH (2432W)
11 Diciembre 2023 - 1:00AM
UK Regulatory
TIDMPOLB
RNS Number : 2432W
Poolbeg Pharma PLC
11 December 2023
Poolbeg Pharma plc
POLB 001 Data Presented at ASH
POLB 001 - targeting Cytokine Release Syndrome (CRS) associated
with cancer immunotherapies
11 December 2023 - Poolbeg Pharma (AIM: POLB, OTCQB: POLBF,
'Poolbeg' or the 'Company'), a biopharmaceutical company focussed
on the development and commercialisation of innovative medicines
targeting diseases with a high unmet medical need and with a lack
of treatment alternatives, announces key insights from its poster
presentation at the prestigious, 65th American Society of
Hematology ('ASH') Annual Meeting and Exposition, San Diego.
The poster, which details POLB 001 as a potential therapy for
Cytokine Release Syndrome ('CRS') associated with cancer
immunotherapies, was presented by Dr Emma Searle from The Christie
Hospital, Manchester, UK on Saturday 9 December.
CRS is a well-recognised toxicity that occurs frequently
following certain cancer treatments such as T-cell engaging
antibodies and CAR T cell therapies. In addition to patient
mortality and morbidity risk, the high frequency of CRS associated
with these treatments represents a barrier to outpatient delivery.
The need for in-patient management of CRS adds to the overall
healthcare costs of delivering these treatments and contributes to
restricting their availability.
Meanwhile, the POLB 001 LPS human challenge trial conducted by
Poolbeg demonstrated good safety and tolerability, a clear
dose-response relationship, inhibition of p38 MAPK activation, and
a reduction in all measured pro-inflammatory cytokines. The effects
observed were a negation of immune over-reaction rather than an
ablation of core immune function. Phase II trial enabling
activities are underway with strong interest from potential pharma
partners.
David Allmond, Chief Business Officer of Poolbeg Pharma,
commented: "The field of cancer immunotherapies, including CAR T
and bispecific antibodies, is burgeoning and expected to grow to
over $100bn by 2030. However, CRS is rate limiting in the delivery
of these potentially lifesaving therapies. There is strong interest
from pharma partners seeking an effective and convenient (orally
administrable) solution to CRS to broaden the utilisation of their
breakthrough immunotherapies. Presenting at ASH is strong
validation of POLB 001's potential and we are delighted to have the
opportunity to continue our productive partnering discussions at
this prestigious conference."
- Ends -
Enquiries
Poolbeg Pharma Plc
Jeremy Skillington, CEO
Ian O'Connell, CFO +44 (0) 207 183 1499
Cavendish Capital Markets Ltd (Nominated
Adviser & Joint Broker)
Geoff Nash, Charlie Beeson, Nigel
Birks, Harriet Ward (ECM) +44 (0) 207 220 0500
Singer Capital Markets (Joint Broker)
Phil Davies, Sam Butcher +44 (0) 207 496 3000
J&E Davy (Joint Broker)
Anthony Farrell, Niall Gilchrist +353 (0) 1 679 6363
About Poolbeg Pharma
Poolbeg Pharma plc is committed to the development and
commercialisation of innovative medicines targeting diseases with a
high unmet medical need. Its model focusses upon developing its
exciting clinical assets and commercialising approved and marketed
drugs to fund the development of its robust pipeline of innovative
products, thereby driving significant value creation.
Poolbeg is led by an experienced leadership team with a history
of delivering significant shareholder value. The team has been
strengthened by the appointment of three former members of the
Amryt Pharma plc leadership team, with the intention of repeating
Amryt's success and generating near term revenues.
Poolbeg's clinical programmes target large addressable markets
including CRS induced by cancer immunotherapies, infectious
disease, and metabolic conditions such as obesity with the
development of an oral GLP-1R agonist. It uses a cost-effective
development philosophy to generate high quality human data to
support partnering and further development. Its AI-led infectious
disease programmes analyse unique data from human challenge trials
to identify clinically relevant drug targets and treatments,
leading to faster development and greater commercial appeal.
For more information, please go to www.poolbegpharma.com or follow us on Twitter and LinkedIn @PoolbegPharma.
About ASH
The ASH Annual Meeting and Exposition is recognised as the
world's premier conference focussing on haematological malignancies
(blood cancers) and brings together over 25,000 industry and
academic attendees each year to share the latest scientific
discoveries and advances in clinical care.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCUPGWPPUPWGMR
(END) Dow Jones Newswires
December 11, 2023 02:00 ET (07:00 GMT)
Poolbeg Pharma (LSE:POLB)
Gráfica de Acción Histórica
De Abr 2024 a May 2024
Poolbeg Pharma (LSE:POLB)
Gráfica de Acción Histórica
De May 2023 a May 2024